Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Mar 17, 2024 2:32pm
89 Views
Post# 35937358

RE:RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024

RE:RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024

Several factors fueled the revival of M&A activity in 2023. Pharma companies have exceptionally strong balance sheets and approximately US$1.37 Trillion of acquisition "firepower". They are taking a hard look at new technologies to build and expand their capabilities. Targets are increasingly seeking to do transactions at stabilizing values, which are premium valuation for late-stage clinical development companies with de-risked assets, such as with ONCY's pelareorep.
 

These factors have staying power, and many life sciences companies are publicly hunting for deals and seeking to shed noncore assets in their quest for value creation. This year promises an active market for M&A in the sector, according to a growing number of global life science consulting companies.
 

To prepare to play and win in this market, life sciences companies are being advised to do some soul-searching. For pharmaceutical companies, this means asking: What assets will build my pipeline and make me a leader in fast-growing segments like cell and gene therapy and biologics? Can my capabilities make the deal economics work? With the passing of the IRA in 2022 by the US government which grants newly approved and orphan drug biologicals 13 years of marketing exclusivity versus 9 years for small molecules, it has become even more evident that ONCY's drug platform in pelareorep can effectively meet the above asks for several Big Pharma companies, who are moving away from small molecules and into a diversified product pipeline of therapeutic biologics.

<< Previous
Bullboard Posts
Next >>